-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82

Benzinga·02/13/2026 11:32:46
Listen to the news
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $80 to $82.